Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
International Care Bundle Evaluation in Cerebral Hemorrhage Research
NCT06429332 · View on ClinicalTrials.gov ↗
Study Summary
Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, intensive care and neurosurgical interventions are uncommon. A study conducted in low- and middle-income countries has demonstrated a beneficial effect of a treatment package consisting of early intensive blood pressure lowering, as well as the treatment of pyrexia and elevated blood glucose levels. The I-CATCHER team is now planning to conduct a similar study in Sweden and Australia, as well as in other high-income countries. The study has a clear focus on implementation, aiming to improve treatment and prognosis for patients with ICH within a few years. The purpose of I-CATCHER is to investigate whether a structured treatment package (Care Bundle) improves 3-month prognosis in patients with spontaneous ICH compared to standard care.
Conditions Studied
Interventions
- OTHER Reversal of Oral anticoagulation within 30 minutes
- OTHER Early intensive blood pressure lowering
- OTHER Treatment of pyrexia
- OTHER Hyperglycemia treatment
- OTHER Do-not-resuscitate (DNR) or withdrawal of care
Study Locations (20)
Other
- Royal Adelaide Hospital — Adelaide
- Monash Medical Centre — Clayton
- The George Institute for Global Health — Sydney
- Hong Kong University Hospital — Hong Kong
- Landspitali University Hospital — Reykjavik
- Avezzano Ospedale SS. Filippo e Nicola — Avezzano
- Citta di Castello Ospedale Città di Castello — Città di Castello
- Gubbio Ospedale di Gubbio e Gualdo Tadino — Gubbio
- Azienda Ospedaliera Santa Maria della Misericordia Perugia — Perugia
- Roma Policlinico Gemelli — Roma
- National University of Malaysia Hospital — Kuala Lumpur
- Universiti Putra Malaysia Hospital — Serdang
- Höglandssjukhuset i Eksjö — Eksjö
- Sahlgrenska Universitetssjukhuset — Gothenburg
- Östra Sjukhuset — Gothenburg
- Hässleholms Sjukhus — Hässleholm
- Helsingborgs Lasarett — Helsingborg
- Karolinska Universitetssjukhuset Huddinge — Huddinge
Oklahoma
- The University of Oklahoma Health — Oklahoma City
Ontario
- Ottawa Hospital Research Institute — Ottawa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,500 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06429332
The ClinicalTrials.gov registry entry for NCT06429332 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Region Skane, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Stroke appearing as the primary indexed condition, and to 5 interventions — of which Reversal of Oral anticoagulation within 30 minutes is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06429332 reports 20 study locations spanning 3 distinct geographic areas — top geographies include Other, Oklahoma, Ontario. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06429332 about?
NCT06429332 is a clinical study titled "International Care Bundle Evaluation in Cerebral Hemorrhage Research". Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, intensive care and neuro...
What is the current status of trial NCT06429332?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 3,500 participants. The study started on 2025-01-07. Estimated completion is 2027-07.
What conditions does trial NCT06429332 study?
This clinical trial studies the following conditions: Stroke, Intracerebral Hemorrhage, Intraventricular Hemorrhage, Cerebrovascular Disease, Intracerebral Haemorrhage. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06429332?
The interventions under investigation include: Reversal of Oral anticoagulation within 30 minutes (OTHER), Early intensive blood pressure lowering (OTHER), Treatment of pyrexia (OTHER), Hyperglycemia treatment (OTHER), Do-not-resuscitate (DNR) or withdrawal of care (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06429332?
This trial is sponsored by Region Skane, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06429332 being conducted?
This trial has 20 study locations across Oklahoma, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.